(Press-News.org) A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month interim analysis of the efficacy of tofacitinib appear in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).
RA is a chronic, autoimmune disease that causes inflammation, pain and swelling of the joints. Over time, RA may destroy joints, impair daily function, and lead to significant disability. The World Health Organization (WHO) estimates that RA affects up to one percent of individuals worldwide and 1.3 million of those are Americans according to the ACR.
"Tofacitinib inhibits Janus kinase (JAK) enzymes that are found in white blood cells, and which help to regulate the immune system," explains lead investigator Dr. Désirée van der Heijde from Leiden University Medical Center in The Netherlands. "We are examining the oral JAK inhibitor, tofacitinib, as a disease-modifying anti-inflammatory drug (DMARD) and for its ability to modulate the immune system in those with RA."
In this 24-month, double-blind, placebo-controlled study, 797 participants were randomized (4:4:1:1) to receive 5 mg of tofacitinib twice daily (BID) (n=321); 10 mg of tofacitinib BID (n=316); placebo to tofacitinib 5 mg BID (n=81); or placebo to tofacitinib10 mg BID (N=79). Participants had a mean age of 53 years, 85% were female, 54% were non-Caucasian, and the mean duration of RA was 9 years. Patients who did not respond to placebo were advanced to tofacitinib at three months and the remaining placebo participants at six months.
Results from a planned 12-month interim analysis from the 24-month, Phase 3 trial show that tofacitinib is effective in preserving joint structure in patients with moderate to severe RA who had an inadequate response to MTX therapy. The difference from placebo in mean change from baseline in the van der Heijde modified total Sharp score was statistically significant for tofacitinib at 10 mg BID but not at 5 mg BID at month 6 (co-primary endpoint) and month 12.
Patients treated with tofacitinib at both 5 and 10 mg BID doses displayed less progression of joint erosion and joint space narrowing compared to placebo at six and twelve months. Change in the joint space narrowing score was statistically significant at month 12 for the tofacitinib groups versus placebo. Researchers also reported that the proportion of patients with no radiographic progression in the tofacitinib groups was significantly greater compared to placebo.
Analysis confirms previous results that tofacitinib is effective in treating RA symptoms and reducing the rate of joint damage. "Our findings provide the first evidence that tofacitinib reduces the progression of structural damage in RA patients with active disease," concludes Dr. van der Heijde.
The U.S. Food and Drug Administration (FDA) approved tofacitinib—the first oral JAK inhibitor for treatment of moderate to severe RA—on November 6, 2012. A twice daily 5 mg dose of tofacitinib was approved by the FDA for RA patients who are unresponsive or intolerant to MTX. The drug is being marketed by Pfizer as Xeljanz®.
INFORMATION:
This study is published in Arthritis & Rheumatism. Media wishing to receive a PDF of the article may contact sciencenewsroom@wiley.com
Full citation: "Tofacitinib (CP-690,550) in Patients with Rheumatoid Arthritis on Methotrexate: 12-Month Data from a 24-Month Phase 3 Randomized Radiographic Study." Desiree van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel Kremer, Cristiano Zerbini, Mario H.Cardiel, Stanley Cohen, Peter Nash, Yeong-Wook Song, Dana Tegzova, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John D. Bradley, Carol A. Connel and the ORAL Scan investigators. Arthritis & Rheumatism; January 24, 2013 (DOI: 10.1002/art.37816).
URL Upon Publication: http://doi.wiley.com/10.1002/art.37816
About the Journal
Arthritis & Rheumatism is an official journal of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP), a division of the College, and covers all aspects of inflammatory disease. The American College of Rheumatology is the professional organization who share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://onlinelibrary.wiley.com/journal/10.1002/art.
About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
END
The first ever review of abuse cases related to child death or serious injury in Northern Ireland will be launched at Queen's University today (24 January 2013). The review, Translating Learning into Action, was commissioned by the Department of Health, Social Services and Public Safety (DHSSPS) and was carried out by researchers at Queen's University and the NSPCC.
The Case Management Review (CMR) report – the first to be produced in Northern Ireland - analysed 24 case reviews relating to 45 children which resulted in death or serious injury in the period between 2003 ...
Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide. This phase I clinical trial enrolled 38 patients, and pomalidomide provided a minimal or better response for 42 percent of the patients, a partial response or better for 21 percent, and a complete response for 3 percent.
The study, a collaborative effort among researchers from Moffitt, Dana-Farber Cancer ...
Using social media to search for sex offenders
Facebook and other social media sites have been increasing their efforts to identify possible child predators that use their sites to reach children and teenagers. While the technology available to Facebook has improved and expanded over time, most online predators are not flagged in the system and end up reaching their victims without ever being stopped or identified. While some arrests are being made through the efforts of these websites, they still face problems trying to make sure that their sites aren't being used to ...
Concussions More Harmful Than Thought, Symptoms Persist for Years
For years physicians, coaches and parents thought that a concussion was something that could be cured with a little rest. Unfortunately, new research is questioning this notion.
Researchers with the University of Oklahoma suggest that the symptoms associated with concussions, also known as traumatic brain injuries, can last years longer than expected. Even more surprising: the symptoms may not decrease in intensity.
Details of the Study
The study focused on the severity and duration of symptoms ...
New law increases penalty for fatal hit-and-run accidents
Leaving the scene of an accident has always been a serious offense. Now, drivers who flee the scene in Pennsylvania face even tougher penalties under a law designed to punish drivers involved in fatal hit-and-run accidents.
Details of the new law
A fatal accident in 2005, involving a 29-year-old man who was hit while riding his bicycle by a driver who fled the scene, prompted the new law, which went into effect in September 2012.
Previously classified as a third-degree felony, fatal hit-and-runs carried ...
Child custody involving grandparents
While grandparents can have a large and important role in a child's life, they do not have a constitutional right to see their grandchildren. The Supreme Court case Troxel v. Granville decided that parents are the individuals with the "fundamental right" to make decisions about the care of their children. Grandparents do not have the same legal rights over the care of their grandchildren, and their rights are limited in comparison to those of a parent. However a lack of a constitutional right to visitation does not mean ...
How small businesses can handle tax audits
You do not have to run an unethical small business in order to be the subject of an audit by the Internal Revenue Service. And even if you have not done anything wrong, that does not make the process any less stressful. The following tips can help you avoid a tax audit, as well as help to deal with the IRS if your business is being audited.
How to avoid a tax audit
Although you may not be intentionally trying to defraud the government when you file your taxes, there are some common mistakes that small businesses make that ...
Lawsuit Accuses Video Game Demonstration Company of Age Discrimination
It is no secret that video games have become popular with people of all ages - whether on a phone, console, or personal computer, video games have become a popular pastime. Nevertheless, despite the acknowledged cross-generational appeal of video games, one video game marketing company has been accused of age discrimination.
According to a lawsuit recently filed in Missouri, Mosaic Sales Solutions US Operating Company - a company that demonstrates Microsoft video game products - requires all job ...
Researchers develop new methods for diagnosing TBI
Traumatic brain injuries are some of the most devastating injuries that can be suffered in a car crash or other accident. Even a minor brain injury can cause severe pain and short-term sensory and cognitive difficulties.
More serious brain injuries can have life-long consequences. Many TBI victims experience severe and persistent headaches. Cognitive problems are also common, including slowed thinking, forgetfulness and trouble with decision making. In addition, many TBI victims experience changes in personality and ...
Halcyon Software, a leading global provider of monitoring, scheduling and automation software, has signed a reseller agreement with SASIT, the Auckland-based Managed Services Provider, to become its first business partner in New Zealand. As sole national reseller, SASIT will provide customers using the IBM i series with access to Halcyon's full range of solutions.
SASIT has been using Halcyon products to manage its own IBM Power Systems running the IBM i operating system since 2011. The company began evaluating systems management products two years ago as significant ...
